Company Description
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States.
Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration.
The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications.
It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine.
The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications.
Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Jeffrey Frelick |
Contact Details
Address: 2 Burlington Woods Drive, Suite 100 Burlington, Massachusetts 01803 United States | |
| Phone | 781 552 4452 |
| Website | bonebiologics.com |
Stock Details
| Ticker Symbol | BBLG |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1419554 |
| CUSIP Number | 098070600 |
| ISIN Number | US0980706008 |
| Employer ID | 42-1743430 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Jeffrey Frelick | Chief Executive Officer and President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 24, 2026 | EFFECT | Notice of Effectiveness |
| Jul 24, 2026 | 424B3 | Prospectus |
| Jul 23, 2026 | 8-K | Current Report |
| Jul 20, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 17, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Jul 16, 2026 | 8-K | Current Report |
| Jul 9, 2026 | 8-K | Current Report |
| Jul 2, 2026 | ARS | Filing |
| Jul 2, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 2, 2026 | DEF 14A | Other definitive proxy statements |